Flumexadol

Pharmacodynamics Flumexadol has been found to act as an agonist of the serotonin 5-HT1A receptor (Ki = 79nM), of the serotonin 5-HT2C receptor (Ki = 32nM), and, to a much lesser extent, of the serotonin 5-HT2A receptor (Ki = 1,000nM). According to Nilsson (2006) in a paper on serotonin 5-HT2C receptor agonists as potential anorectics, "The (+)-enantiomer of this compound showed [...] affinity for the 5-HT2C receptor (Ki) 25 nM) [...] and was 40-fold selective over the 5-HT2A receptor in receptor binding studies. The racemic version [...], also known as 1841 CERM, was originally reported to possess analgesic properties while no association with 5-HT2C receptor activity was mentioned." ==Chemistry==

Synthesis File:Flumexadol synthesis.svg|thumb|center|500px|class=skin-invert-image|Thieme Synthesis: Patent: Halogenation of 2-chloroethyl vinyl ether (1) with molecular bromine gives 1,2-dibromo-1-(2-chloroethoxy)ethane (2). Grignard reaction with 3-bromobenzotrifluoride (3) gives 1-[2-bromo-1-(2-chloroethoxy)ethyl]-3-(trifluoromethyl)benzene (4). Treatment with benzylamine gives 4-benzyl-2-[3-(trifluoromethyl) phenyl]morpholine (5). Catalytic hydrogenation strips the benzyl protecting group completing the synthesis of flumexadol (6). == See also ==